Evaluating liver-protecting effect of tiopronin, bifendatatum, and glycyrrhizinate through three liver disease indicators (ALT, AST, and LDH release). Dose 1, 2, 3, and 4 referred to the experimental section. (a) ALT release after treated with hepatoprotectants, (b) AST release after treated with hepatoprotectants, and (c) LDH release after treated with hepatoprotectants.